No Data
IGM Biosciences to Present at the Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred
In-Depth Examination Of 6 Analyst Recommendations For IGM Biosciences
IGM Biosciences (NASDAQ:IGMS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below offers a condensed view of the
H.C. Wainwright Maintains IGM Biosciences(IGMS.US) With Hold Rating, Maintains Target Price $12
H.C. Wainwright analyst Robert Burns maintains $IGM Biosciences(IGMS.US)$ with a hold rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.4%
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Maintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical Data
Express News | HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target